Drug intelligence / Profile preview

ERI-0001

Development stage: Preclinical
Lead developer: Novatium Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ERI-0001 is an investigational chimeric antigen receptor (CAR) T-cell therapy being developed by Novatium in partnership with Factor Bioscience. It is engineered to dually target CD5 and B-cell maturation antigen (BCMA), markers found on malignant plasma cells and certain autoreactive immune cells. By targeting these antigens, ERI-0001 aims to provide a potent therapeutic option for high-risk multiple myeloma (HrML) and systemic lupus erythematosus (SLE). The program is currently in the IND-enabling phase, utilizing Factor Bioscience's cell-engineering technologies to create a therapy capable of targeted killing of malignant or autoreactive cells.

Other names: CD5-BCMA CAR-T cell therapyCD-5-BCMA CAR-T cell therapyCD 5-BCMA CAR-T cell therapy

Beyond the preview

Go deeper on ERI-0001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERI-0001.

Explore the full profile